CMS(CNMMY)
Search documents
招商证券(06099) - 2025年度初步财务数据
2026-01-27 12:45
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其 準確性或完整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 6099 2025年度初步財務數據 本公告由招商證券股份有限公司(「本公司」)根據證券及期貨條例(香港法例第571章)第 XIVA部之內幕消息條文(定義見香港聯合交易所有限公司證券上市規則(「上市規則」))及 上市規則第13.09條及第13.10B條而作出。 本公告所載之截至2025年12月31日止年度(「本報告期」)主要財務數據和指標為初步財務 數據,乃根據中國企業會計準則編製且未經審計。最終財務數據以本公司2025年年度報 告所披露者為準。 本公司預計本公司及其附屬公司截至2025年12月31日止年度的經審計業績將根據上市規 則的規定於2026年3月31日或之前刊發。 | 項目 | 本報告期末 | 本報告期初 | (%) | | --- | --- | --- | --- | | 總資產 | 75,334,988.48 | 72,116,033.14 | 4.46 | | 歸屬於母公司股東的權益 | ...
招商证券(600999.SH)2025年度归母净利润123亿元,同比增长18.43%
智通财经网· 2026-01-27 11:15
智通财经APP讯,招商证券(600999.SH)披露2025年度业绩快报,2025年实现营业总收入249亿元,同比 增长19.19%;归属于母公司股东的净利润123亿元,同比增长18.43%。 2025年,公司积极融入国家经济社会大局,以服务金融"五篇大文章"为战略引领,强化协同联动,实现 发展质量和经营效益稳步提升。 ...
招商证券:预计2025年归母净利润123亿元,同比增18.43%
Bei Jing Shang Bao· 2026-01-27 10:43
| 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- | --- | | 营业总收入 | 2,489,959.05 | 2,089,139.80 | 19.19 | | 营业利润 | 1,399,007.28 | 1,122,766.43 | 24.60 | | 利润息额 | 1,402,590.39 | 1,121,949.16 | 25.01 | | 归属于母公司股东的净利润 | 1,229,973.71 | 1,038,587.24 | 18.43 | | 归属于母公司股东的扣除非经常 | 1,224,877.13 | 1.037.677.27 | 18.04 | | 基本每股收益(人民币元/股) | 1.35 | 1.13 | 19.47 | | 加权平均净资产收益率(%) | 9.90 | 8.82 | 增加 1.08 个百分点 | | | 本报告期末 | 本报告期初 | 增减变动幅度(%) | | 总资产 | 75,334,988.48 | 72,116,033.14 | 4.46 | | 归属于母公司股东的权益 | 13,795,851.94 | ...
招商证券:2025年度净利润约123亿元,同比增加18.43%
Sou Hu Cai Jing· 2026-01-27 09:34
每日经济新闻 (记者 王晓波) 免责声明:本文内容与数据仅供参考,不构成投资建议,使用前请核实。据此操作,风险自担。 每经AI快讯,招商证券1月27日晚间发布2025年度业绩快报,营业收入约249亿元,同比增加19.19%; 归属于上市公司股东的净利润约123亿元,同比增加18.43%;基本每股收益1.35元,同比增加19.47%。 每经头条(nbdtoutiao)——国际金价冲破5000美元!7年涨了280%,什么时候才见顶?专家:关键还 看美元,重点关注国际货币体系、降息和科技革命 ...
招商证券(600999) - 2025 Q4 - 年度业绩


2026-01-27 09:20
证券代码:600999 证券简称: 招商证券 编号:2026-001 招商证券股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载 2025 年度主要财务数据和指标为初步核算数据,未经会计师事 务所审计,具体数据以招商证券股份有限公司(以下简称公司或本公司)2025 年度的定期报告中披露的数据为准,提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位:人民币万元 1 2025 年,公司积极融入国家经济社会大局,以服务金融"五篇大文章"为 战略引领,强化协同联动,实现发展质量和经营效益稳步提升。2025 年,本公 司实现营业总收入人民币 249.00 亿元,实现归属于母公司股东的净利润人民币 123.00 亿元。 三、风险提示 本公告所载 2025 年度主要财务数据和指标为初步核算数据,可能与公司 2025 年年度报告中披露的数据存在差异,具体数据以公司 2025 年年度报告中披 露的数据为准,提请投资者注意投资风险。 四、备查文件 经公司现任法定代表人霍达先生、主管 ...
招商证券:2025年净利润123亿元 同比增长18.43%
Ge Long Hui A P P· 2026-01-27 09:09
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 格隆汇1月27日|招商证券(600999.SH)发布2025年度业绩快报,营业总收入为248.99亿元,同比增长 19.19%;归属于母公司股东的净利润为122.99亿元,同比增长18.43%。 ...
盛视科技2025净利预降 2020上市募11.6亿招商证券保荐
Zhong Guo Jing Ji Wang· 2026-01-27 07:51
Core Viewpoint - Shengshi Technology (002990.SZ) has announced its 2025 annual performance forecast, expecting a significant decline in net profit attributable to shareholders, projecting between 62 million to 87 million yuan, which represents a decrease of 50.26% to 64.55% compared to the previous year [1][2]. Financial Performance Summary - The projected net profit attributable to shareholders for 2025 is between 62 million yuan and 87 million yuan, down from 174.90 million yuan in the previous year, indicating a decline of 50.26% to 64.55% [1][2]. - The net profit after deducting non-recurring gains and losses is expected to be between 51 million yuan and 72 million yuan, a decrease of 50.79% to 65.15% from 146.32 million yuan in the previous year [1][2]. - Basic earnings per share are projected to be between 0.24 yuan and 0.33 yuan, compared to 0.69 yuan in the previous year [2]. Revenue and Profit Trends - The company's revenue for 2023 and 2024 is projected to be 1.573 billion yuan and 1.222 billion yuan, respectively, reflecting a decline of 22.31% in 2024 [3][4]. - The net profit attributable to shareholders for 2023 and 2024 is expected to be 198.23 million yuan and 174.90 million yuan, showing a decrease of 11.77% in 2024 [3][4]. - The net profit after excluding non-recurring gains and losses for 2023 and 2024 is projected to be 172.22 million yuan and 146.32 million yuan, indicating a decline of 15.04% in 2024 [4].
招商证券:锂电池新一轮扩产进入加速阶段 锂电设备厂商有望迎来新增量
智通财经网· 2026-01-27 06:47
Group 1 - The lithium battery industry is entering an accelerated expansion phase, with major companies starting a new round of capital expenditures in 2025, and 2026 is expected to see record-high capex investments [1] - The demand for lithium batteries has consistently exceeded expectations in recent years, leading to order overflow from major manufacturers due to insufficient capacity, with an estimated additional production capacity of nearly 1 TWh expected in 2026 [1] - Major lithium battery manufacturers are currently initiating equipment tenders, with hundreds of GWh of orders already visible, and further orders of around 100 GWh are anticipated [1] Group 2 - Orders for lithium battery equipment have reached new highs, with most equipment manufacturers showing positive year-on-year growth in contract liabilities, and many have surpassed historical peaks [2] - The strong order situation in the lithium battery equipment sector is expected to continue into 2026, although profitability improvements may not be realized until 2026 [2] Group 3 - Progress has been made in the research and development of solid-state batteries, with a shift in focus towards cost reduction and efficiency improvements in equipment, laying the groundwork for future testing of solid-state batteries [3] - Major battery manufacturers are expected to begin constructing pilot lines for solid-state batteries in 2026, which will create additional demand and opportunities for equipment companies [3] Group 4 - Companies to watch in this sector include XianDao Intelligent (300450.SZ), XianHui Technology (688155.SH), LianYing Laser (688518.SH), HaiMuXing (688559.SH), DeLong Laser (688170.SH), ST YiFei (688646.SH), YingHe Technology (300457.SZ), HangKe Technology (688006.SH), and XinYuRen (688573.SH) [4]
奥科达医药递表港交所 招商证券国际、建银国际为联席保荐人
Zheng Quan Shi Bao Wang· 2026-01-27 01:20
奥科达医药向港交所递交上市申请,招商证券国际、建银国际为其联席保荐人。公司拥有自主研发的创 新的药物递送平台,搭建了覆盖研发、生产及销售和营销的一体化内部体系,并组建了丰富的全球产品 管线。 公司的核心产品是AUC033与AUC051。AUC033A于2023年5月通过505(b)(2)路径在美国获批上市。 AUC051,为一款临床阶段的产品,有望在美国及中国获批上市。 中枢神经系统(CNS)疾病市场是制药行业规模最大、最复杂的治疗领域之一,其市场规模仅次于肿瘤领 域。全球中枢神经系统药物市场涵盖了抑郁症、焦虑症、偏头痛、帕金森病、阿尔茨海默病及癫痫等多 种疾病,目前正经历强劲增长。2020年至2024年期间,全球中枢神经系统药物市场从2337亿美元增加至 2588亿美元,复合年增长率为2.6%;预计到2033年将达到3482亿美元,2024年至2033年期间的复合年 增长率为3.3%。 ...
芯原股份连亏3年 A股两募资共36.7亿IPO招商证券保荐
Zhong Guo Jing Ji Wang· 2026-01-26 07:48
Core Viewpoint - Chip Origin Co., Ltd. (芯原股份) has announced its 2025 annual performance forecast, projecting a revenue increase but continued net losses, indicating a narrowing of losses compared to previous years [1] Financial Performance Summary - The company expects to achieve an operating revenue of approximately 3.153 billion yuan in 2025, representing a growth of 35.81% compared to 2024 [1] - The projected net profit attributable to shareholders for 2025 is approximately -449 million yuan, which is a reduction of 152 million yuan from the previous year, reflecting a narrowing of losses by 25.29% [1] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is approximately -627 million yuan, with a reduction of 16 million yuan compared to the previous year, indicating a narrowing of losses by 2.49% [1] - Historical revenue figures for 2022 to 2024 are 2.679 billion yuan, 2.338 billion yuan, and 2.322 billion yuan respectively [1] - Historical net profit figures for the same period are 73.81 million yuan, -296 million yuan, and -601 million yuan respectively [1] - Historical net profit figures after deducting non-recurring gains and losses are 13.29 million yuan, -318 million yuan, and -643 million yuan respectively [1] - The net cash flow from operating activities for the years 2022 to 2024 are -329 million yuan, -8.52 million yuan, and -346 million yuan respectively [1] Fundraising and IPO Details - Chip Origin Co., Ltd. was listed on the Sci-Tech Innovation Board on August 18, 2020, with an issuance of 48.3193 million shares at a price of 38.53 yuan per share, raising a total of 1.862 billion yuan [2] - The net amount raised after deducting issuance costs was 1.678 billion yuan, which was 888 million yuan more than the original plan [2] - The company planned to use the raised funds for various projects, including IP application solutions for smart wearable devices, smart cars, smart homes, and upgrading the R&D center [2] - The total issuance costs for the IPO were 184 million yuan, with underwriting fees amounting to 164 million yuan [3] - In a subsequent issuance on July 3, 2025, the company issued 24,860,441 shares at a price of 72.68 yuan per share, raising a total of approximately 1.807 billion yuan, with a net amount of approximately 1.780 billion yuan after costs [3][4]